Content Quality: Well-structured News piece (Overview / What We Know / What We Don't Know / Analysis) at 753 words, within the 400-1200 word range for the News category. Clear, professional prose with appropriate hedging in the 'What We Don't Know' section (no disclosed raise amount, share price range, or underwriters).
Source Verification: Both sources fetched successfully (HTTP 200) and their sha256 checksums verified against manifest.json. Read sources/2026-07/scribe-therapeutics-files-for-nasdaq-ipo-testing-investor-appetite-for-early-stage-crispr-gene-editing-biotechs/source-0.html.gz (BioPharma Dive, 'Gene editing developer Scribe plots an IPO', published July 6, 2026, byline Gwendolyn Wu) and source-1.html.gz (BioSpace, 'Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios', published July 6, 2026, byline Tristan Manalac). Both are reputable, on-topic biotech trade publications and correctly attributed in the article.
Factual Accuracy: Checked every specific in the article against the two snapshots. Confirmed verbatim/accurate: SEC prospectus filed July 2 (BioSpace: 'prospectus filed July 2'); Nasdaq Global Market ticker 'SCTX' (both sources); Scribe launched 2020, CEO Benjamin Oakes ex-Doudna researcher (BioPharma Dive); BioSpace's exact phrase 'the Jennifer Doudna-founded biotech' reproduced verbatim in quotes; $120M raised from Andreessen Horowitz/Avoro Ventures/OrbiMed and $25M+ CIRM grant (BioPharma Dive); Sanofi $25M upfront + $40M 2023 expansion (BioPharma Dive); Lilly/Prevail deal worth up to $1.5B with two milestones hit (BioPharma Dive); Biogen ALS collaboration announced shortly after 2020 launch (BioPharma Dive); STX-1150 mechanism, PCSK9 target, single-dose vs. Repatha/Praluent comparison, entered clinic in June (BioPharma Dive); BioSpace's exact phrases 'recently entered a first-in-human study in Australia' and 'according to the biotech's prospectus' reproduced verbatim in quotes; STX-1200 (Lp(a)) and STX-1400 (triglycerides) preclinical programs (BioSpace); '14th venture-backed biotech to price an IPO in 2026' (BioPharma Dive); Kardigan $400M June raise (both sources agree); Metagenomi ~$94M 2024 IPO as last gene-editing IPO (BioPharma Dive); Parabilis $670M June raise and Kailera $625M April raise (BioSpace); Ben Zercher/PitchBook quote reproduced verbatim and correctly attributed to BioSpace (BioSpace). One nuance scrutinized: the article states the Lilly/Prevail milestones 'generated two milestone payments' where BioPharma Dive's more hedged phrasing is 'hit two milestone achievements, making Scribe eligible for two unspecified payments' -- in standard biotech deal structure, hitting a milestone is what triggers/generates the associated payment, so this is a reasonable paraphrase rather than a fabrication or overstatement; it does not affect the headline, summary, or lead and is not flagged as a correction. The internal link to the May 26, 2026 TGA-clearance article was verified against that article's own content (TGA clearance, STX-1150, PCSK9) and is accurate. No fabricated quotes, no hallucinated statistics, no orphan source URLs (all external links in body_markdown map to the two declared sources; the one internal /article/ link is not a claim needing external sourcing).
Overall Assessment: Exceptionally well-sourced News submission. Every specific fact, figure, and direct quote traces cleanly to one of the two cited trade-press sources, both of which are reputable and correctly attributed. Headline, summary, and lead are all fully supported. No corrections needed.